19) The answer is C. Let’s review. Meta-analysis of 11 trials thru April 2021. In CKD no difference in total adverse events vs placebo (RR = 1.02, p=0.08) In dialysis patients no difference in adverse events vs ESA (RR= 1.22, p=0.18) See 🔓https://t.co/NAcK
2,581 followers
297 followers
RT @IronBiologyBot: Paper alert: Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and…
297 followers
Paper alert: Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis https://t.co/bip66LU9ys #IronBiology #BioIron #Iron
3,017 followers
New Research: Safety and Efficacy of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis: Background: Roxadustat, a hypoxia-inducible factor prolyl-hydroxylase… https://t.co/SUL2bLjX5W #medicalcare #